Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Ministry Reviews Thalidomide For Multiple Myeloma

This article was originally published in PharmAsia News

Executive Summary

The Ministry of Health, Labor and Welfare began a review panel meeting Aug. 26 to consider thalidomide as a treatment for multiple myeloma, on condition that adverse event prevention methods are fully addressed. The MHLW panel will consider safety measures put forth by pharmaceutical companies, such as registration requirements for pharmacists, physicians and patients and establishment of a third party to monitor compliance. Upon completion of the review the drug could be launched as early as the end of the year. Japan has 13,000-14,000 multiple myeloma patients. Thalidomide is approved to treat multiple myeloma in 17 countries. (Click here for more - Japanese language)

You may also be interested in...

Japan Re-approves Thalidomide For Cancer Treatment

TOKYO - Japan's Ministry of Health, Labor and Welfare has approved re-listing thalidomide, which Japan banned in 1962 for causing serious human deformations, to be marketed by Fujimoto Pharmaceutical, officials of the ministry's Pharmaceutical and Food Bureau and the Insurance Bureau confirmed Oct. 7

Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971

It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform to ISO 14971:2019.

Crosswalk: ISO 14971:2007 Vs. ISO 14971:2019

Here’s a crosswalk for recently revised international risk management standard ISO 14971 and its 2007 predecessor.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts